Pfizer has indicated they don't intend to make any further application for use of the vaccine beyond the two doses and a booster dose, although for some people they, effectively, receive four doses, although a growing body of international evidence suggests that it would be a useful thing for a further dose to be available to some parts of the population. The vaccine is available to anybody whose GP is prepared to prescribe it on an off-label basis, and so what is being sought here is not something that is out of the realms of possibility otherwise, but it would be an enormous exercise, of course, if everybody who wanted to get it as a further reassurance because of waning efficacy had to go to the GP, had to seek a prescription off-label, and had to go through that process. This simply allows the director-general who would be required in terms of the amendment bill to obtain appropriate advice, which the director-general would do, to allow the vaccine to be available on a broader basis.